Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Epilepsy Behav ; 156: 109797, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38788658

RESUMO

PURPOSE: We aimed to identify factors that contribute to the discontinuation of perampanel. METHODS: We retrospectively analyzed patients with epilepsy at the Department of Psychiatry, Hokkaido University Hospital. We evaluated the factors contributing to perampanel discontinuation as primary outcomes using Cox proportional hazards regression. Then, we explored the components contributing to the primary outcomes using logistic regression analysis. RESULTS: A total of 118 patients were included, 44.9% of whom discontinued participation, 22.0% had intellectual disability, and 23.7% had a psychiatric disorder other than intellectual disability. Adverse effects occurred in 65% of the patients, 23.7% had psychiatric adverse effects (PAE), and 49.2% had common adverse effects (CAE). The effect of PER to suppress seizures was confirmed in 65.3% of them. Discontinuation was influenced by non-response (Hazard Ratio (HR) 6.70, 95% Confidence Interval (CI) 3.42-13.1), the occurrence of PAE (HR 3.68, 95% CI 1.89-7.16), CAE (HR 1.90, 95% CI 1.06-3.41), and comorbid psychiatric disorders (HR 2.35, 95% CI 1.21-4.59). Moreover, comorbid intellectual disability correlated with a low risk of PAE (OR 0.19, 95% CI 0.04-0.89). CONCLUSION: The discontinuation of perampanel is influenced by poor efficacy and the occurrence of common/psychiatric adverse effects. The discontinuation of perampanel is influenced by poor efficacy and the occurrence of common/psychiatric adverse effects. Consideration of factors contributing to perampanel discontinuation may assist in determining the indication for perampanel treatment.


Assuntos
Anticonvulsivantes , Transtornos Mentais , Nitrilas , Piridonas , Humanos , Piridonas/efeitos adversos , Piridonas/uso terapêutico , Nitrilas/efeitos adversos , Feminino , Masculino , Estudos Retrospectivos , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/uso terapêutico , Pessoa de Meia-Idade , Adulto , Transtornos Mentais/epidemiologia , Transtornos Mentais/tratamento farmacológico , Epilepsia/tratamento farmacológico , Epilepsia/epidemiologia , Idoso , Adulto Jovem , Deficiência Intelectual/epidemiologia , Adolescente
2.
Biol Pharm Bull ; 47(4): 764-770, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38569835

RESUMO

L-Lactate transport via monocarboxylate transporters (MCTs) in the central nervous system, represented by the astrocyte-neuron lactate shuttle (ANLS), is crucial for the maintenance of brain functions, including memory formation. Previously, we have reported that MCT1 contributes to L-lactate transport in normal human astrocytes. Therefore, in this study, we aimed to identify transporters that contribute to L-lactate transport in human neurons. SH-SY5Y cells, which are used as a model for human neurons, were differentiated using all-trans-retinoic acid. L-Lactate uptake was measured using radiolabeled L-lactate, and the expression of MCT proteins was confirmed Western blotting. L-Lactate transport was pH-dependent and saturated at high concentrations. Kinetic analysis suggested that L-lactate uptake was biphasic. Furthermore, MCT1, 2 selective inhibitors inhibited L-lactate transport. In addition, the expression of MCT1 and 2 proteins, but not MCT4, was confirmed. In this study, we demonstrated that MCT1 and 2 are major contributors to L-lactate transport in differentiated human neuroblastoma SH-SY5Y cells from the viewpoint of kinetic analysis. These results lead to a better understanding of ANLS in humans, and further exploration of the factors that can promote MCT1 and 2 functions is required.


Assuntos
Neuroblastoma , Simportadores , Humanos , Cinética , Transporte Biológico , Proteínas de Transporte/metabolismo , Ácido Láctico/metabolismo , Proteínas de Membrana Transportadoras/metabolismo , Transportadores de Ácidos Monocarboxílicos/metabolismo , Simportadores/metabolismo
3.
Chem Commun (Camb) ; 60(37): 4946-4949, 2024 May 02.
Artigo em Inglês | MEDLINE | ID: mdl-38629254

RESUMO

A novel C-N axially chiral molecule composed of two tert-butyl-substituted benzo[b]phenoxazine (BPO) was synthesized via solvent-free reactions. The absolute configurations of the enantiomers were determined by X-ray single-crystal analysis. The enantiomers had a sufficiently high racemization barrier to ignore racemization at room temperature (149 ± 20 kJ mol-1), and the solutions exhibited dual circularly polarized emissions stemming from fluorescence and phosphorescence of |gCPL| = ca. 1 × 10-3.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA